Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Current Osteoporosis Reports Pub Date : 2023-12-14 DOI:10.1007/s11914-023-00833-3

Tatiane Vilaca, Richard Eastell

{"title":"Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes","authors":"Tatiane Vilaca, Richard Eastell","doi":"10.1007/s11914-023-00833-3","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of the Review</h3><p>The purpose of the review is to summarise the current scientific evidence on the efficacy of osteoporosis medications in patients with type 2 diabetes.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Type 2 diabetes (T2D) is a growing global epidemic. The highest prevalence is observed in the elderly, the same population affected by osteoporosis. Despite normal or even increased bone mineral density and low bone turnover, T2D is associated with an increased risk of fractures in most skeletal sites. These findings raised concerns over the efficacy of anti-osteoporosis drugs in this population. There is no randomised controlled trial designed specifically for people with T2D. However, observational studies and post-hoc analyses of randomised controlled trials have provided valuable insights into the effects of various anti-osteoporosis treatments in this population. Overall, most anti-osteoporosis drugs seem to have similar efficacy and safety profiles for people with and without type 2 diabetes. However, continued research and long-term safety data are needed to optimise treatment strategies and improve bone health outcomes in this population.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>The current evidence suggests that most anti-osteoporosis drugs exhibit comparable efficacy in people with and without T2D.</p>","PeriodicalId":11080,"journal":{"name":"Current Osteoporosis Reports","volume":"74 1","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-023-00833-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of the Review

The purpose of the review is to summarise the current scientific evidence on the efficacy of osteoporosis medications in patients with type 2 diabetes.

Recent Findings

Type 2 diabetes (T2D) is a growing global epidemic. The highest prevalence is observed in the elderly, the same population affected by osteoporosis. Despite normal or even increased bone mineral density and low bone turnover, T2D is associated with an increased risk of fractures in most skeletal sites. These findings raised concerns over the efficacy of anti-osteoporosis drugs in this population. There is no randomised controlled trial designed specifically for people with T2D. However, observational studies and post-hoc analyses of randomised controlled trials have provided valuable insights into the effects of various anti-osteoporosis treatments in this population. Overall, most anti-osteoporosis drugs seem to have similar efficacy and safety profiles for people with and without type 2 diabetes. However, continued research and long-term safety data are needed to optimise treatment strategies and improve bone health outcomes in this population.

Summary

The current evidence suggests that most anti-osteoporosis drugs exhibit comparable efficacy in people with and without T2D.

Abstract Image

查看原文本刊更多论文

骨质疏松症药物对 2 型糖尿病患者的疗效

本综述的目的是总结目前关于骨质疏松药物治疗2型糖尿病患者疗效的科学证据。2型糖尿病(T2D)是一种日益增长的全球流行病。患病率最高的是老年人，同样是骨质疏松症患者。尽管骨密度正常甚至增加，骨周转率低，但T2D与大多数骨骼部位骨折风险增加有关。这些发现引起了人们对抗骨质疏松药物在这一人群中的疗效的关注。目前还没有专门为T2D患者设计的随机对照试验。然而，观察性研究和随机对照试验的事后分析为各种抗骨质疏松治疗在这一人群中的效果提供了有价值的见解。总的来说，大多数抗骨质疏松药物似乎对2型糖尿病患者和非2型糖尿病患者具有相似的疗效和安全性。然而，需要持续的研究和长期的安全性数据来优化治疗策略和改善这一人群的骨骼健康结果。目前的证据表明，大多数抗骨质疏松药物对t2dm患者和非t2dm患者的疗效相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Osteoporosis Reports Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

8.80

自引率

2.30%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.